Losan Pharma GmbH Company Profile
The company, Losan Pharma GmbH, established under the direction of Dr. Peter Sandmeier in 1993, has had a remarkable beginning. Today 200 workers produce over 1000 batches and over 10 mil. packages per year for both clients within Germany and throughout the world. Further, positive development is expected - an expansion of the production area is planned. Apart from flexibility and swiftness, the most modern equipment and laboratories distinguish Losan Pharma's constant search for innovations. Our specialities are the development and manufacture of improved generics, "Generics Plus."
Location
Otto-Hahn-Str. 13
Neuenburg
D-79395
Germany
Contact
Phone: 49 (0) 7631 - 7906 0
Fax: 49 (0) 7631 - 7906 99
Email: info@losan.de
News Articles
Pharma 3.0 Pulls Companies into the Digital Future
Social media and mobile marketing have kick-started the pharma industry into a phase dubbed Pharma 3.0. Gone are the days of Pharma 1.0 in which companies could rely on a handful of blockbuster drug...
Big pharma companies BMS and Merck are pharma partnering on Daclatasvir
Big pharma company, Bristol-Myers Squibb, is pharma partnering with another big pharma company, Merck, to develop Daclatasvir to treat Hepatitis C. The big pharma companies will work on the hepatitis...
Merck enter pharma partnering pact with Ra Pharma for cyclomimetics
Ra Pharmaceuticals has entered into a pharma partnering deal with Merck, a top 50 big pharma corporation, focused on the development of Cyclomimetics, a new class of compounds that have the diversity...
Verona Pharma plc: Analyst Presentation on the Company Website
LONDON, April 10, 2013 /PRNewswire/ -- Verona Pharma plc ("Verona Pharma" or the "Company") Verona Pharma plc (VRP: London Stock Exchange) ("Verona Pharma", or the "Company"), the biotechnology co...
Big Pharma performance continues to receive muted reviews from various analysts and industry commentators. Pharma Reform starts with an analysis of drug approvals in 2012 by FDA. It is TRUE that 35 dr...
Bad Pharma by Dr Ben Goldacre; the mechanics of a mediocre argument
Nick Broughton discusses Dr Ben Goldacre’s latest book, Bad Pharma, and comments on why he believes it was a wasted opportunity for the pharma industry. If you are working in pharma and are not awa...
Pharma IQ’s Top Pharma Bloggers of 2013
Pharma IQ put out it’s list of the Top Pharma Bloggers for 2013. These lists tend to be subjective and always leave off many great sites. But, these can be a good way to discover a blog you have...
Catalent and UMN Pharma Announce Collaboration for Biosimilar Development and Production in Japan
Catalent Pharma Solutions and UMN Pharma Inc. today announced the signing of an agreement to provide UMN Pharma a broad range of biosimilar cell lines using Catalent’s proprietary GPEx ® techno...
Drugs and Medications
Fluoride [Libertas Pharma, Inc.]
Fluoride Chewable Tablets 0.5 mg
Fluoride [Libertas Pharma, Inc.]
Fluoride Chewable Tablets 1 mg
Metoprolol tartrate [Med-Health Pharma, LLC]
Metoprolol Tartrate Tablets, USP
Rx Only 45% Urea Nail Gel In a vehicle containing Camphor, Eucalyptus Oil and Menthol )
PubMed Articles
Structures containing the (R)-3-amino-3-methyl piperidine unit as a new pharmacophore moiety have been shown to possess moderate inhibitory activity for DPP-4 with good pharmacokinetics profile. One o...
Is pharma running out of brainy ideas?
Clinical Trials
To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.
Pharma-Pen (Formerly Innoject) Auto-Injectory TIV
The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...
To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions
To demonstrate the relative bioavailability of Cilostazol 50 mg tablets under fasting conditions.
This is 2-armed parallel group, prospective, randomized, open-label, multicenter Phase 3 controlled trial to establish the efficacy and safety of conversion from maintenance immunosuppress...
Development of a New Method for Analgesia
Aim: To examine a new method to perform local anesthesia in order to diminish the inconvenience by the procedure in patients before performing intubation or oesophagogastroduodenoscopy.
Companies
The company, Losan Pharma GmbH, established under the direction of Dr. Peter Sandmeier in 1993, has had a remarkable beginning. Today 200 workers produce over 1000 batches and over 10 mil. packages pe...
H3 Pharma Inc. is a Venture Pharma focusing on the development of human therapeutic products oriented towards age-related disorders. At H3 Pharma, we aim to be the best at identifying, evaluating and...
LEO Pharma Inc. is headquartered in Parsippany, New Jersey, and is the U.S. affiliate of Denmark-based LEO Pharma A/S, a global leader in dermatology and critical care with more t...
Laurantis Pharma Oy is a privately held specialty pharmaceutical company based in Finland. Laurantis Pharma Oy was formed in 2010 through the merger of two independent companies,...
FranceMed Pharma is a Research, Development, FMCG Manufacturer and Global Marketing Company established since 1981. FranceMed Pharma owns Magicool® brand and the world-wide patents and technology. Fr...
More Information about "Losan Pharma GmbH" on BioPortfolio
We have published hundreds of Losan Pharma GmbH news stories on BioPortfolio along with dozens of Losan Pharma GmbH Clinical Trials and PubMed Articles about Losan Pharma GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Losan Pharma GmbH Companies in our database. You can also find out about relevant Losan Pharma GmbH Drugs and Medications on this site too.
